CORDIS · FrEBT

Improving diagnostics of respiratory diseases and boosting the COMAC MEDICAL Ltd. competitiveness and growth by validation of fractional EBT biomarker through new method of measurement and device

Код

FrEBT

Програма

H2020

Процедура

PHC-12-2015-1

Статус

CLOSED

Период

01.09.2015 – 31.10.2015

Официални данни · CORDIS · синхронизирано 21.10.2026 03:41 · официален запис

Участници

Описание

The innovation project objectives are to: 1/prove through a feasibility study the potential to validate the Fractional Exhaled Breath Temperature, via new viable and disruptive technological device, as a diagnostic, prognostic and monitoring biomarker for inflammatory and obstructive pulmonary diseases; 2/enhance the competitiveness and profitability of the full- service clinical research organization COMAC MEDICAL Ltd., operating via own network of partners in 14 countries from 3 European regions with population of over 118 mln.The commercial potential of the innovative solution is that it is a best alternative of the existing methods on market, saving great number of diagnosis‘ stages without any potential risk for the patients, being more precise, user friendly, non-invasive, less painful, faster, cost effective, covering vulnerable groups of children, young and elderly people, saving lives, increasing workforce capabilities.It is a response to the EU wide and global challenges related to the respiratory diseases causing high level of morbidity and mortality–at about 1 million deaths annually in the European Region; 2/3 of them in EU28, with total cost there of € 380 bln.The expected SME growth is 20%, leading to specialisation in Pulmonology and Oncology and filling a market niche. The SME will launch into new markets in Europe and Asia, increasing its market share in clinical trials - 12-15% in Bulgaria;10% in Europe and 2-5% worldwide. The outcome of the Phase1 project is a feasibility study, assessing the socio-economic, commercial, technical aspects of the innovation, based on 6 steps of activities on: the Description of the innovative solution;Market/Technical Feasibility;Financial/Economic Feasibility; Organizational/Managerial Feasibility;Risk assessment;IP Management.The targeted users are the patients through the healthcare systems and the doctors, specialists in respiratory diseases and lung cancer as well as the GPs.

Официални данни · CORDIS · синхронизирано 21.10.2026 03:41 · официален запис · Лиценз: © European Union, CC BY 4.0 (Commission reuse policy).